Your browser doesn't support javascript.
Integrins as Therapeutic Targets for SARS-CoV-2.
Gressett, Timothy E; Nader, Danielle; Robles, Juan Pablo; Buranda, Tione; Kerrigan, Steven W; Bix, Gregory.
  • Gressett TE; Tulane University School of Medicine, Clinical Neuroscience Research Center (CNRC), New Orleans, LA, United States.
  • Nader D; Department of Neurology, Tulane University School of Medicine, New Orleans, LA, United States.
  • Robles JP; Tulane Brain Institute, Tulane University, New Orleans, LA, United States.
  • Buranda T; RCSI University of Medicine and Health Sciences, School of Pharmacy and Biomolecular Sciences (PBS), Dublin, Ireland.
  • Kerrigan SW; Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Juriquilla, Mexico.
  • Bix G; University of New Mexico Health Sciences Center (HSC), Department of Pathology, Albuquerque, NM, United States.
Front Cell Infect Microbiol ; 12: 892323, 2022.
Article in English | MEDLINE | ID: covidwho-1952260
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Front Cell Infect Microbiol Year: 2022 Document Type: Article Affiliation country: Fcimb.2022.892323

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Front Cell Infect Microbiol Year: 2022 Document Type: Article Affiliation country: Fcimb.2022.892323